The Effect of Blood Selenium Level on the pCR Rate in Breast Cancer Patient Receiving Neoadjuvant Chemotherapy.

PURPOSE

Among patients treated with neoadjuvant chemotherapy (NAC), a high survival rate is observed for those who experience a pathological complete response (pCR). Various tumor factors are predictive of a pCR, but few host factors have been studied.We sought to inquire whether or not a patient's blood selenium level prior to treatment was predictive of a pCR.

METHODS

We studied 329 women diagnosed with primary invasive breast cancer who were treated with neoadjuvant chemotherapy (NAC). We included patients with HER2-positive ( = 183) or triple-negative breast cancer ( = 146). Blood was collected before the initiation of treatment. Blood levels of selenium were quantified by mass spectroscopy. Each patient was assigned to one of three tertiles based on the distribution of blood selenium levels in the entire cohort. Patients with triple-negative breast cancer (TNBC) were treated with a range of combination chemotherapies. Patients with HER2-positive breast cancer received anti-HER2 treatment based on trastuzumab alone or trastuzumab and pertuzamab. After treatment, each patient was classified as having pCR or no pCR.

RESULTS

In the entire cohort, the pCR rate was 59.0% for women in the highest tertileof blood selenium (≥107.19 μg/L) compared to 39.0% for women in the lowest tertile (≤94.29 μg/L) ( = 0.003).

CONCLUSIONS

A high selenium level is predictive of pCR in women treated for HER2-positive or triple-negative breast cancer. If confirmed, this observation may lead to a study investigating if selenium supplementation improves pCR rates and survival in breast cancer women receiving NAC.